Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2024-11-10 Epub Date: 2024-06-25 DOI:10.1200/JCO.24.00539

Natansh D Modi, Sandra M Swain, Marc Buyse, Nicole M Kuderer, Andrew Rowland, Frank W Rockhold, Michael J Sorich, Ashley M Hopkins

引用次数: 0

Abstract

Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes.

查看原文本刊更多论文

美国食品和药物管理局批准的抗癌药物的临床研究报告和个体参与者数据透明度：呼吁提供系统性数据。

通过全面的企业社会责任（CSR）和 IPD 共享来释放临床试验的全部潜能，可以彻底改变癌症护理、加强安全性评估并减少系统性综述中的偏差。现在是所有利益相关者接受透明度并推进以患者为中心的结果的时候了。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.